Market and Overview
The World Health Organization estimates up to 1 Billion cases of Obstructive Sleep Apnea worldwide, with only 20% of cases being diagnosed. Further, a 2020 investigation published in the Journal of Clinical Sleep Medicine found that patients with untreated sleep apnea incur a cost of $19,566 per year more than patients in a control group (treated). The increase in cost is a result of higher in-patient care, emergency visits, readmissions, prescription costs, and other points of service. A 2016 study by Frost and Sullivan found that untreated sleep apnea costs the United States economy nearly 150 billion dollars annually in motor vehicle accidents, workplace accidents, and lost productivity.
Further, a recent 155-page document published by the Agency for Health Research and Quality (attached) suggests the current “gold standard” of therapy, Continuous Positive Airway Pressure (CPAP), lacks greatly in managing sleep apnea. While alternative therapies continue to enter the market, oral appliance therapy (OAT) is currently covered by the Centers for Medicaid and Medicare Services and recommended as first-line therapy for mild to moderate sleep apnea by the American Academy of Sleep Medicine. Patients that have used both CPAP and OAT, strongly prefer OAT report wearing their oral appliance three years after beginning therapy (86%).
Provisional patents pending
Get updates about the latest developments from Dianyx Innovations and learn more about our first-of-its-kind wearable for monitoring sleep apnea patients.
450 Alkyre Run Drive STE 300 Westerville OH 43082